Top movers in Monday's session Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Cogent Biosciences Hits 7-Year High, Up 120% On Its New Stomach Cancer Promise The company is working to improve outcomes for patients with gastrointestinal stromal tumors, or GIST.
Let's uncover which stocks are experiencing notable gaps during today's session. In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial Cogent Biosciences stock rises as bezuclastinib plus Sutent shows 50% lower progression risk and strong efficacy in Phase 3 GIST trial.
Monday's pre-market session: top gainers and losers The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results Cogent Biosciences (
NASDAQ: COGT ) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from its SUMMIT clinical trial for bezuclastinib. This investigational drug, aimed at non-advanced systemic mastocytosis (NonAdvSM), demonstrated significant efficacy and a favorable
3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags According to the technical analysis of over 4,400 firms with a market cap exceeding $100 million, three firms are in the overbought zone.
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges Bezuclastinib met all primary and secondary endpoints in a Phase 3 trial for non-advanced systemic mastocytosis, with analysts highlighting strong efficacy, safety, and commercial potential.
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.
US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns' U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benchmark indices were trading mixed.
Let's uncover which stocks are experiencing notable gaps during today's session. Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Why Is Cogent Biosciences Stock Trading Higher On Monday? Cogent reported positive SUMMIT trial data for bezuclastinib in NonAdvSM and plans to file for FDA approval by late 2025.
